Several studies detected abnormal mi-RNAs expression levels in childhood Acute Lymphoblastic Leukemia (ALL) with potential diagnostic value.
Pneumonia is a major cause of death of children in low and middle income countries (LMICs). In this issue of the European Respiratory Journal, Nguyen et al. [1] examine pneumonia care in a large secondary care hospital in Vietnam...
“A new frontier in cancer treatment” for acute lymphoblastic leukemia (ALL).
Amgen has announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase III...
Novartis announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL 019 (tisagenlecleucel), an investigational...
Advances in genomic research and risk-directed therapy have led to improvements in the long-term survival and quality of life outcomes of patients with childhood acute lymphoblastic leukaemia (ALL)
The primary end point of the phase III PhALLCON study (NCT03589326) was met as first-line ponatinib (Iclusig) ,from Takeda and Incyte, plus reduced-intensity chemotherapy outperformed imatinib (Gleevec) for the treatment of patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL)
A still major question in the field of acute lymphoblastic leukemia (ALL) in children - an extremely heterogeneous disease though curable in 80-90% of children and 70-80% of the adolescents - is the optimal use of L-asparaginase (ASNase).
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive...
Amgen announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive...